Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a pre-revenue company: Net cash floor and Analyst consensus.
ACCE opinionWhitehawk Therapeutics Inc. Common Stock (WHWK)
Fair value
Not available
ACCE price target
$2.90
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $3.21 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Net cash floor.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
29
out of 100
Analysts
67% buy
9 covering
1-year return
+31.0%
Dividend yield
0.00%
Whitehawk Therapeutics Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
I can't tell you what Whitehawk Therapeutics makes from the data provided, since the figures here cover only valuation and profitability ratios and say nothing about its pipeline, product or indication. What the numbers do show is a biotech at roughly $173M market cap with revenue down 100% (effectively no revenue recognised in the period), a gross margin of -1,183.7%, an ROE of -45%, and no index membership. The 0.0 trailing P/E reflects losses rather than cheapness, and the 2.7 forward P/E is not meaningful without a forecast earnings base I can verify. The composite score of 31/100 is weak. Before this earns a deeper look, the team needs the pipeline, cash runway versus burn, and the timing of any clinical or regulatory readouts, none of which are in this dataset.
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
severe
Negative free cash flow
Free cash flow is $-97,985,000 against an ~$182M market cap, and revenue fell 100% year over year. The company is burning roughly half its market value in one year of cash outflow.
high
No revenue, negative gross margin
Gross margin is -1183.7% and ROE is -45.0%, with no operating or net profit to offset the cash burn. Forward P/E of -3.2 shows analysts still expect losses.
high
Insider selling, no buying
Insiders disclosed $3.07M in sales and $0.00M in purchases across the last 10 filings. Insiders hold 12.6% of shares.
moderate
Price above ACCE target
The stock trades 10.7% above the ACCE price target of $2.90, with the current price at $3.21. The ACCE score slipped from 32 to 29 over 90 days.
AI research notes
AI-assisted·How I use AIWritten Oct 21, 2026 · figures from 2026-10-21 · prices to Oct 23, 2026
Why it could do well
Analysts are broadly positive, with 67% (6 of 9) rating the stock Buy or Strong Buy.
The average analyst price target of $7.71 sits 141.8% above the current share price.
Whitehawk beat its latest earnings estimate, reporting EPS of -0.20 against -0.30 expected, a 33.3% surprise.
Why it could disappoint
Free cash flow over the last 12 months was -$98M, so the business is burning cash rather than generating it.
Revenue fell 100.0% year over year, and the company has no profit, with a net margin of 0.0%.
The diluted share count rose 129.0% last fiscal year, so each shareholder's slice of the company has shrunk sharply.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where WHWK's valuation models land
Price
$3.21
Model fair valueConfidence: low
about $5.26
Model
Fair value
Upside
Analyst consensus
Net cash floor
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores